6N2K

Tetrahydropyridopyrimidines as Covalent Inhibitors of KRAS-G12C


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.72 Å
  • R-Value Free: 0.172 
  • R-Value Work: 0.118 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

Fell, J.B.Fischer, J.P.Baer, B.R.Ballard, J.Blake, J.F.Bouhana, K.Brandhuber, B.J.Briere, D.M.Burgess, L.E.Burkard, M.R.Chiang, H.Chicarelli, M.J.Davidson, K.Gaudino, J.J.Hallin, J.Hanson, L.Hee, K.Hicken, E.J.Hinklin, R.J.Marx, M.A.Mejia, M.J.Olson, P.Savechenkov, P.Sudhakar, N.Tang, T.P.Vigers, G.P.Zecca, H.Christensen, J.G.

(2018) ACS Med Chem Lett 9: 1230-1234

  • DOI: 10.1021/acsmedchemlett.8b00382
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • <i>KRAS </i> is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly associated with poor prognosis and resistance to standard treatment. The ability to effectively target and block the function of mutated KRA ...

    KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutations are commonly associated with poor prognosis and resistance to standard treatment. The ability to effectively target and block the function of mutated KRAS has remained elusive despite decades of research. Recent findings have demonstrated that directly targeting KRAS-G12C with electrophilic small molecules that covalently modify the mutated codon 12 cysteine is feasible. We have discovered a series of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity. The PK/PD and efficacy of compound 13 will be highlighted.


    Organizational Affiliation

    Array BioPharma, Inc., 3200 Walnut Street, Boulder, Colorado 80301, United States.,Mirati Therapeutics, Inc., 9393 Towne Centre Drive, Suite 200, San Diego, California 92121, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
GTPase KRas
A
170Homo sapiensMutation(s): 4 
Gene Names: KRAS (KRAS2, RASK2)
Find proteins for P01116 (Homo sapiens)
Go to Gene View: KRAS
Go to UniProtKB:  P01116
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GDP
Query on GDP

Download SDF File 
Download CCD File 
A
GUANOSINE-5'-DIPHOSPHATE
C10 H15 N5 O11 P2
QGWNDRXFNXRZMB-UUOKFMHZSA-N
 Ligand Interaction
MG
Query on MG

Download SDF File 
Download CCD File 
A
MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N
 Ligand Interaction
K9J
Query on K9J

Download SDF File 
Download CCD File 
A
1-{4-[2-{[(2R)-1-(dimethylamino)propan-2-yl]oxy}-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl}propan-1-one
C29 H38 N6 O3
XWVXFKORKNADOR-HXUWFJFHSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.72 Å
  • R-Value Free: 0.172 
  • R-Value Work: 0.118 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 39.969α = 90.00
b = 49.975β = 90.00
c = 92.623γ = 90.00
Software Package:
Software NamePurpose
MOSFLMdata reduction
PHASERphasing
PDB_EXTRACTdata extraction
REFMACrefinement
Aimlessdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2018-11-13 
  • Released Date: 2018-12-12 
  • Deposition Author(s): Vigers, G.P.

Revision History 

  • Version 1.0: 2018-12-12
    Type: Initial release
  • Version 1.1: 2019-01-23
    Type: Data collection, Database references